Alpha-1A adrenergic receptor · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-12Alpha-1A adrenergic receptor shows approved-linked disease relevance led by benign prostatic hyperplasia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P35348. Start with benign prostatic hyperplasia, then reuse UniProt P35348 as the stable protein anchor across project notes and exports.
Start with benign prostatic hyperplasia, then reuse UniProt P35348 as the stable protein anchor across project notes and exports.
Alpha-1A adrenergic receptor shows approved-linked disease relevance led by benign prostatic hyperplasia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with benign prostatic hyperplasia because it currently carries approved-linked support. Linked drugs include SILODOSIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyAlpha-1A adrenergic receptor
Review this target as Alpha-1A adrenergic receptor, mapped to UniProt P35348. Sequence length is 466 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Alpha-1A adrenergic receptor as ChEMBL target CHEMBL229, mapped to UniProt P35348. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Alpha-1A adrenergic receptor is the right protein anchor across sources, using UniProt P35348 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why benign prostatic hyperplasia is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Alpha-1A adrenergic receptor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P35348 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Alpha-1A adrenergic receptor |
| UniProt Accession | P35348 |
| Component Type | Protein |
| Sequence Length | 466 aa |
Alpha-1A adrenergic receptor
Review this target as Alpha-1A adrenergic receptor, mapped to UniProt P35348. Sequence length is 466 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Alpha-1A adrenergic receptor shows approved-linked disease relevance led by benign prostatic hyperplasia. 5 more disease programs remain visible in the same review block.
Start review with benign prostatic hyperplasia because it currently carries approved-linked support. Linked drugs include SILODOSIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL145843 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL145547 | 10.7 | Ki | 0.02 | Preclinical |
| CHEMBL10085 | 10.7 | Ki | 0.02 | Clinical |
| CHEMBL836 | 10.54 | Ki | 0.029 | Approved |
| CHEMBL24778 | 10.44 | Ki | 0.036 | Approved |
| CHEMBL2 | 10.4 | Ki | 0.04 | Approved |
| CHEMBL292189 | 10.4 | Ki | 0.03981 | Preclinical |
| CHEMBL324090 | 10.4 | Ki | 0.04 | Clinical |
| CHEMBL341849 | 10.3 | Ki | 0.05 | Preclinical |
| CHEMBL42472 | 10.3 | Ki | 0.05012 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 349 | 734 | 7.7 |
| cell-based format | 116 | 629 | 7.8 |
| tissue-based format | 19 | 129 | 8.8 |
| cell membrane format | 11 | 11 | 7.5 |
| assay format | 10 | 145 | 6.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 57 | 212 | 7.3 |
| assay format | 42 | 164 | 7.7 |
| tissue-based format | 24 | 31 | 6.9 |
| cell membrane format | 1 | 1 | 6.6 |
| single protein format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 11 | 19 | 7.1 |
| cell-based format | 4 | 23 | 6.9 |